Stepan Company Earnings Call Transcripts
Fiscal Year 2026
-
A 90-year specialty chemicals firm is seeing strong margin recovery, with Q2 EBITDA up 45% and broad-based 6% volume growth. Strategic focus on innovation, diversification, and operational excellence—highlighted by Project Catalyst—drives margin expansion and positions the company for continued growth in higher-margin segments.
-
Adjusted EBITDA rose 45% to $74 million on broad-based volume growth, margin recovery, and Project Catalyst savings, with net sales up 15% year-over-year. Q2 benefited from some customer pre-buying, and full-year guidance anticipates continued EBITDA growth and deleveraging.
-
Q1 2026 saw 4% organic net sales growth and record safety, but adjusted EBITDA fell 14% year-over-year due to surfactant headwinds and a major restructuring charge. Project Catalyst is on track, with most savings expected to ramp up in Q2.
Fiscal Year 2025
-
2025 saw EBITDA growth, improved leverage, and strong free cash flow despite sector headwinds. Project Catalyst aims for $100M in savings, with most benefits and demand recovery expected in H2 2026. Surfactants faced margin pressure, while Polymers and Specialty Products showed growth.
-
Q3 2025 saw 6% adjusted EBITDA growth, led by specialty products, while net income fell 54% due to higher tax and depreciation. Surfactants faced margin pressure from raw material costs, but polymers and specialty products showed volume gains. Free cash flow was strong at $40.2 million.
-
The presentation highlighted strategic investments, global expansion, and a focus on high-growth markets such as agriculture and insulation. Despite recent sales declines due to raw material fluctuations, key segments returned to growth in 2024. Management remains committed to innovation, customer expansion, and shareholder returns.
-
Q2 2025 saw 8% adjusted EBITDA growth and a 27% rise in adjusted net income, led by Polymers and Crop Productivity, despite raw material inflation and one-time costs. The Pasadena plant ramp-up and asset optimization are expected to drive further gains.
-
Q1 2025 saw 12% adjusted EBITDA growth and 32% higher adjusted net income, led by strong surfactant and specialty product performance, while polymers lagged. The new Pasadena site is operational, with full impact expected in H2 2025, and tariff impacts are being closely monitored.
Fiscal Year 2024
-
Q4 2024 Adjusted EBITDA fell 7% year-over-year, but full-year Adjusted EBITDA rose 4% despite significant one-time costs. Surfactants and Specialty Products delivered strong growth, offset by weak Polymers demand. The Pasadena facility is set to drive further gains in 2025.
-
Q3 Adjusted EBITDA rose 11% year-over-year to $53 million, led by surfactant growth, while polymers faced macro headwinds. New CEO Luis Rojo expects continued Free Cash Flow improvement and positive momentum as the Pasadena facility comes online.
-
Adjusted EBITDA grew 4% year-over-year in Q2 2024, with strong volume recovery in most core markets but continued softness in agriculture and operational challenges at Millsdale. The company expects improved second-half earnings, positive free cash flow, and the Pasadena facility to support future growth.